CN1676165A - In vivo slow-releasing anticancer medicinal composition - Google Patents
In vivo slow-releasing anticancer medicinal composition Download PDFInfo
- Publication number
- CN1676165A CN1676165A CN 200410075842 CN200410075842A CN1676165A CN 1676165 A CN1676165 A CN 1676165A CN 200410075842 CN200410075842 CN 200410075842 CN 200410075842 A CN200410075842 A CN 200410075842A CN 1676165 A CN1676165 A CN 1676165A
- Authority
- CN
- China
- Prior art keywords
- vinorelbine
- acid
- pharmaceutical composition
- tartaric acid
- plant alkaloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an anti-cancer medicine composition which can be slowly-released in human body. Said composition comprises medicinal auxiliary material and plant alkaloids anti-cancer medicine, in white the plant alkaloids anti-cancer medicine can inhibit hyperplasia of tumor, and the medicinal auxiliary material mainly can be bio-compatible high-molecular polymer which can be degraded and absorbed, in the course of its degradation and absorption the plant alkaloid can be slowly released in tumor locality, so that at the same time of obviously reducing systematic toxic it can retain effective medicine concentration in tumor locality so as to obtain good therapeutic effect.
Description
(1) technical field
The present invention relates to the slow anticancer pharmaceutical composition that discharges in a kind of body, belong to technical field of pharmaceuticals.
(2) background technology
The treatment of entity tumor mainly comprises methods such as operation, radiotherapy and chemotherapy.In used various chemotherapeutics, the action effect of plant alkaloid kind anti-cancer drugs is comparatively obvious, has been widely used in multiple malignant tumor.Yet, further discover, entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, therefore, conventional chemotherapy is difficult to tumor by local and forms effective drug level (referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82), improve the restriction that dosage is subjected to general reaction again merely.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of anticancer pharmaceutical composition is provided.
Anticancer pharmaceutical composition of the present invention, comprise anticancer effective component and pharmaceutic adjuvant, anticancer effective component is the salt of plant alkaloid or plant alkaloid, described plant alkaloid is selected from leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, Podophyllinic Acid (mitopodozide), the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, vinorelbine (Vinorelbine, Vinorebine), Vinorelbine monotartrate, Vinorelbine tartrate, Vinmegallate (Vinmegallate), vinleurosine (Vinleurosine), vinleucinol (Vinleucinol), vinglycinate (Vinglycinate), Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine (Vinfosiltine), vinformide (Vinformide), vinflunine (Vinflunine), vinepidine (Vinepidine), vindesine (Vindesine, vindesine), vinzolidine (Vinzolidine), vintriptol (Vintriptol), vinrosidine (Vinrosidine), oxymatrine, cephalotaxin (Cephalotaxin), 3(R)-Deoxyharringtonine, homoharringtonine (Homoharringtonine), aranotin, monocrotaline (Monocrotaline), maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali.
The salt of above-mentioned plant alkaloid is selected from sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, tartrate, succinate or maleate.
Above plant alkaloid and salt thereof can singly select or multiselect.But with leurosidine, Changchun indole, Changchun chlormethine, vinpocetine, vinorelbine, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, cephalotaxin, procarbazine, vinorelbine and cephalotaxin serves as preferred.
The salt of above-mentioned plant alkaloid or plant alkaloid shared ratio in compositions is decided because of concrete condition, can be good with 1%-50% from 0.01%-99.99%, is best with 2%-30%.
Above-mentioned pharmaceutic adjuvant comprises one of following or its combination:
(1) biocompatibility polymer, comprise biodegradable or biological nondegradable polymer and composition thereof or copolymer, (2) water-soluble low-molecular chemical compound is or/and (3) are used to realize the suitable additive and the excipient of pharmaceutical dosage forms such as injection and slow releasing agent.
Above-mentioned biodegradable polymer comprises natural and/or synthetic polymer.Synthetic polymer as, but be not limited to polyanhydrides, polyhydroxy acid, polyester (polyesters), polyamide (polyamides), poe (polyorthoesters), polyphosphazene (polyphosphazenes), to carboxy phenyl propane (p-CPP), certain herbaceous plants with big flowers diacid (sebacicacid), polifeprosan (to the copolymer of carboxy phenyl propane and certain herbaceous plants with big flowers diacid) etc.; Natural polymer as, but be not limited to, protein and polysaccharide comprise hyaluronic acid, collagen protein, gelatin, albumin etc.
Above-mentioned polyanhydrides can be selected for use, but is not limited to, fragrant polyanhydride, aliphatic polyanhydride; Wherein fragrant polyanhydride will be separated slower, the fusing point height, and dissolubility is low in the organic solvent, however the copolymer of fragrant polyanhydride and aliphatic polyanhydride is comparatively desirable (United States Patent (USP) 4757128) but.Representative wherein is polifeprosan (to the copolymer of carboxy phenyl propane (p-CPP) and certain herbaceous plants with big flowers diacid (SA)), and is fragrant polyanhydride to carboxy phenyl propane, and the certain herbaceous plants with big flowers diacid then is the copolymer of an aromatic diacid and a fat diacid.The copolymer of available other fragrance or aliphatic polyanhydride has a detailed description in other United States Patent (USP) that (US 4857311; 4888176; 4789724).
Above-mentioned polyhydroxy acid can be selected for use, but is not limited to, the copolymer (PLGA) of mixture, glycolic and the hydroxy carboxylic acid of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid (PLA) and polyglycolic acid; When PLA and PLGA mixing, its content percentage by weight is respectively 0.1-99.9% and 99.9-0.1%.The molecular weight of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 10,000-50000 is preferred, with 10,000-20000 is for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 10,000-50000 is preferred, with 10,000-20000 is for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 1000-100,000, but with 10,000-50000 is preferred; With 10,000-20000 is for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or certain herbaceous plants with big flowers diacid or copolymer for most preferably, as, but be not limited to, molecular weight is 5000 to 10000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 20000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 5000 to 10000 polylactic acid mixes with the certain herbaceous plants with big flowers diacid, molecular weight is that 30000 to 80000 PLGA mixes with the certain herbaceous plants with big flowers diacid.
The nondegradable polymer of above-mentioned biology comprises, but be not limited to: organosilicon polymer, ethylene vinyl acetate copolymer (Ethelene-vinyl acetate copolymer, EVAc), polyacrylonitrile (polyacrylonitriles), polyurethanes (polyurethanes) and polyphosphazene (polyphosphazenes) etc.Compositions can discharge effective ingredient by the mode of direct diffusion.
For regulating other characteristic of drug releasing rate or change anticancer pharmaceutical composition of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar and salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt and sodium salt etc.
The used pharmaceutic adjuvant of anticancer pharmaceutical composition of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLGA, glycolic and hydroxy carboxylic acid, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Pharmaceutic adjuvant has a detailed description in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor).In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above pharmaceutic adjuvant has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
The effective ingredient of anticancer pharmaceutical composition can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.In addition, the effective ingredient of anticancer pharmaceutical composition also can be packaged in the liposome equably, or makes microsphere with art methods.
Characteristics of the present invention are that used pharmaceutic adjuvant removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other pharmaceutic adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Pharmaceutic adjuvant also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned pharmaceutic adjuvant is applicable to the compositions that contains or do not contain additive.
Anticancer pharmaceutical composition of the present invention can be made into multiple dosage form.As, but be not limited to injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc.; Be different shape, as, but be not limited to graininess, lamellar, sphere, bulk, needle-like, bar-shaped or mould shape.In various dosage forms, serve as preferred with implant, slow releasing agent and implantation slow release agent.Above-mentioned dosage form and shape are applicable to the compositions that contains or do not contain additive.
Because anticancer pharmaceutical composition of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.
Route of administration
Anticancer pharmaceutical composition of the present invention can be used through various approach, as in passages through which vital energy circulates, tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Route of administration depends on multiple factor, for obtaining valid density in position, tumor place, medicine can give through other number of ways, as arterial perfusion optionally, administration in the intra-bladder instillation (intracavitary), abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and canalis spinalis.In number of ways, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, the form that slowly discharges of tumor week or tumor chamber serve as preferably, can plant slow-releasing pump and slow releasing capsule as selecting for use, body is implanted into agent, sustained-release implant.
Dosage
The consumption of cancer therapy drug depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But effective dose commonly used is 0.01-80 milligram/kg body weight, is ideal with 1-50 milligram/kg body weight, with 2-10 milligram/kg body weight for the most desirable.Ratio shared in compositions is decided because of concrete condition, can be good with 1%-50% from 0.01%-99.99%, is best with 2%-30%.Below all be weight percentage.
Anticancer pharmaceutical composition of the present invention can be used to prepare the various entity tumors for the treatment of the people, comprises former or the cancer of transfer or the medicine of sarcoma or carcinosarcoma originating from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
Anticancer pharmaceutical composition of the present invention also can be used for the treatment of the various entity tumors of house pet and animal, and when being used for the treatment of the various entity tumor of house pet and animal, the material of species specificity is preferably selected in the active ingredient of anticancer pharmaceutical composition of the present invention for use.
Also can add other medicinal ingredient in the anticancer pharmaceutical composition of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Above medicinal ingredient can singly select or multiselect, can join the compositions that contains or do not contain additive, and its content is because of specifically deciding.
Anticancer pharmaceutical composition of the present invention can be used in the following manner.
Above-mentioned effective ingredient is packaged in the pharmaceutic adjuvant, then topical application.Said composition can be through various administrations, with topical, as selective arterial injection and directly injection or be placed as goodly in the tumor body, wherein implant with the part again and slowly are released to the best.When used the part, anticancer pharmaceutical composition of the present invention can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Anticancer pharmaceutical composition Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.
Anticancer pharmaceutical composition can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be good with 1%-50% from 0.1%-99.9%, be best with 2%-30%.This anticancer pharmaceutical composition can be made into various dosage forms, as, but be not limited to injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc.; Be different shape, as, but be not limited to graininess, lamellar, sphere, bulk, needle-like, bar-shaped or mould shape; Can be good with the tremulous pulse approach through various administrations, directly be placed as the best in the tumor body.Most preferred dosage form of the present invention is the implantation slow release agent that bio-capacitivity, degradable absorb, and can make different shape because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and composition for treating solid tumor also can be packed in the liposome.
The characteristics of anticancer pharmaceutical composition technology of preparing of the present invention are one or more plant alkaloid kind anti-cancer drugs are packaged in the pharmaceutic adjuvant, and proportionally with active ingredient and pharmaceutic adjuvant dissolving, the universe is dry afterwards to wait to fill part mixing.Treat that the universe is shaped immediately after dry and sterilizes packing.The local placement not only can overcome the toxic reaction that the whole body administration brings, and solved the tumor by local drug level and cross the low and cell sensitive question to medicine.
The present invention be processed into anticancer pharmaceutical composition preparation method as follows:
1. the pharmaceutic adjuvant of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.
2. adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and pharmaceutic adjuvant is decided because of specific requirement.
3. removal organic solvent.Vacuum drying, cold drying or cold drying all can.
4. dried solid composite is made different shape as required.
5. ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
In a word, the anticancer pharmaceutical composition that contains above effective ingredient can be made into any dosage form or shape, the effective ingredient of anticancer compound is any one (or multiple) plant alkaloid kind anti-cancer drugs, but serving as preferred with implant, agent for slow releasing and implantation agent for slow releasing.
(4) specific embodiment
The present invention is processed into anticancer pharmaceutical composition and further is illustrated by following examples, but is not limited thereto.
Embodiment 1.
With the 90mg molecular weight is that 10000 PLGA (copolymer of hydroxyacetic acid and glycolic, weight ratio 50: 50) puts into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds the 10mg vinorelbine, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the anticancer pharmaceutical composition of percentage by weight 10% vinorelbine.
Embodiment 2.
The method step that is processed into anticancer pharmaceutical composition is identical with embodiment 1, and different is that contained effective ingredient is:
(a) 1-50% leurosidine, Changchun indole, Changchun chlormethine, oxo bridge vinblastine, Podophyllinic Acid, tartaric acid F 81097, tartaric acid leurosine, leurosine, tartaric acid catharanthine, Hainanensine, Hainanolide or vinpocetine; Or
(b) 1-50% liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine; Or
(c) 1-50% vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone or Mei Dengsu; Or
(d) tazettine, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali before 1-50% rubescensine A, pretazettine, the hydrochloric acid.
Below all be weight percentage.
Embodiment 3.
80mg pharmaceutic adjuvant ethylene vinyl acetate copolymer (EVAc) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 20mg cephalotaxin, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the anticancer pharmaceutical composition of percentage by weight 20% cephalotaxin.The drug release time of said composition in external normal saline is 14-24 days, is 20-35 days at the subcutaneous drug release time of mice.
Embodiment 4.
The method step that is processed into anticancer pharmaceutical composition is identical with embodiment 3, and different is that contained effective ingredient is:
(a) 2-30% leurosidine, Changchun indole, Changchun chlormethine, oxo bridge vinblastine, Podophyllinic Acid, tartaric acid F 81097, tartaric acid leurosine, leurosine, tartaric acid catharanthine, Hainanensine, Hainanolide or vinpocetine; Or
(b) 2-30% liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine; Or
(c) 2-30% vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone or Mei Dengsu; Or
(d) tazettine, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali before 2-30% rubescensine A, pretazettine, the hydrochloric acid.
Below all be weight percentage.
Embodiment 5.
70mg polifeprosan (to carboxy phenyl propane: certain herbaceous plants with big flowers diacid copolymer, weight ratio 40: 60) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 30mg vindesine, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the anticancer pharmaceutical composition of percentage by weight 30% vindesine.The drug release time of this anticancer pharmaceutical composition in external normal saline is 15-25 days, is 25-40 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method step that is processed into anticancer pharmaceutical composition is identical with embodiment 5, and different is that effective ingredient is respectively:
(a) 1-50% leurosidine, Changchun indole, Changchun chlormethine, oxo bridge vinblastine, Podophyllinic Acid, tartaric acid F 81097, tartaric acid leurosine, leurosine, tartaric acid catharanthine, Hainanensine, Hainanolide or vinpocetine; Or
(b) 1-50% liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine; Or
(c) 1-50% vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone or Mei Dengsu; Or
(d) tazettine, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali before 1-50% rubescensine A, pretazettine, the hydrochloric acid.
Below all be weight percentage.
Embodiment 7.
The method step that is processed into anticancer pharmaceutical composition is identical with embodiment 1,3 or 5, different is used pharmaceutic adjuvant is following one of a)-e):
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,25000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,10000-20000,25000-35000 or 30000-50000 and the copolymer of hydroxyacetic acid (PLGA);
C) ethylene vinyl acetate copolymer (EVAc);
D) to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) copolymer (polifeprosan), to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40, all is weight percentage
E) xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or albumin.
Embodiment 8.
With the 80mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) copolymer) put into container, after adding 100 milliliters of dichloromethane dissolving mixings, add 10mg vindesine and 10mg vinorelbine, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the anticancer pharmaceutical composition of percentage by weight 10% vindesine and 10% vinorelbine.The drug release time of this anticancer pharmaceutical composition in external normal saline is 15-25 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 9.
The method step that is processed into anticancer pharmaceutical composition is identical with embodiment 8, and different is that effective ingredient is respectively:
(a) combination of 10% vinorelbine and 20% leurosidine, Changchun indole, Changchun chlormethine, oxo bridge vinblastine, Podophyllinic Acid, tartaric acid F 81097, tartaric acid leurosine, leurosine, tartaric acid catharanthine, Hainanensine, Hainanolide or vinpocetine; Or
(b) combination of 10% vinorelbine and 20% liquor epinephrinae bitartratis ophthalmicus, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine; Or
(c) combination of 10% vinorelbine and 20% vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone or Mei Dengsu; Or
(e) combination of tazettine, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali before 10% vinorelbine and 20% rubescensine A, pretazettine, the hydrochloric acid.
Below all be weight percentage.
Tumor-inhibiting action in the body of embodiment 10. plant alkaloid kind anti-cancer drugs.
With the white mice is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 7 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd to 4 group is leurosidine, and the 5th to 7 group is the Changchun indole, and the 8th to 10 group is the Changchun chlormethine.Medicine is placed (itp) respectively in lumbar injection (ip), intratumor injection (it) and tumor.Local leurosidine, Changchun indole and the Changchun chlormethine of placing is all from embodiment 4 (a), and drug dose is 5mg/kg, and the percentage by weight of medicine in implant is respectively 10%, 20% and 30%.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 10th day.
Table 1
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ?1(6) | Contrast | ??50.5±10.5 | |
| ?2(6) | Leurosidine (ip) | ??21±5.0 | ??＜0.05 |
| ?3(6) | Leurosidine (it) | ??12±3.5 | ??＜0.01 |
| ?4(6) | Leurosidine (itp) | ??8±1.8 | ??＜0.01 |
| ?5(6) | Changchun indole (ip) | ??24±4.3 | ??＜0.01 |
| ?6(6) | Changchun indole (it) | ??22±4.6 | ??＜0.01 |
| ?7(6) | Changchun indole (itp) | ??10±1.6 | ??＜0.001 |
| ?8(6) | Changchun chlormethine (ip) | ??26±5.6 | ??＜0.001 |
| ?9(6) | Changchun chlormethine (it) | ??18±1.6 | ??＜0.001 |
| ?10(6) | Changchun chlormethine (itp) | ??6±0.6 | ??＜0.001 |
Tumor-inhibiting action in the body of embodiment 11. plant alkaloid kind anti-cancer drugs.
EXPERIMENTAL DESIGN is with embodiment 10, and local leurosidine, Changchun indole and the Changchun chlormethine of placing is all from embodiment 4 (no), and drug dose is 5mg/kg, and the percentage by weight of medicine in implant is respectively 10%, 20% and 30%, (seeing Table 2).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd to 4 group is vinorelbine, and the 5th to 7 group is Vinmegallate, and the 8th to 10 group is vinleurosine.Medicine is placed (itp) respectively in lumbar injection (ip), intratumor injection (it) and tumor.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 2) on the 10th day.
Table 2
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ?1(6) | Contrast | ????78±14 | |
| ?2(6) | Vinorelbine (ip) | ????46±6.0 | ＜0.05 |
| ?3(6) | Vinorelbine (it) | ????38±4.3 | ＜0.01 |
| ?4(6) | Vinorelbine (itp) | ????26±2.4 | ＜0.01 |
| ?5(6) | Vinmegallate (ip) | ????56±8.0 | ＜0.01 |
| ?6(6) | Vinmegallate (it) | ????34±3.0 | ＜0.01 |
| ?7(6) | Vinmegallate (itp) | ????18±2.0 | ＜0.001 |
| ?8(6) | Vinleurosine (ip) | ????52±5.6 | ＜0.001 |
| ?9(6) | Vinleurosine (it) | ????24±3.6 | ＜0.001 |
| ?10(6) | Vinleurosine (itp) | ????12±3.6 | ＜0.001 |
Tumor-inhibiting action in the body of embodiment 12. plant alkaloid kind anti-cancer drugs.
EXPERIMENTAL DESIGN is with embodiment 10, and the local medicine of placing is that 10% vinorelbine, 20% cephalotaxin and 30% vindesine are respectively from embodiment 1,3 and 5.Drug dose is 5mg/kg, and the percentage by weight of medicine in implant is respectively 10%, 20% and 30%, (seeing Table 3).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd to 4 group is vinorelbine, and the 5th to 7 group is Vinmegallate, and the 8th to 10 group is vinleurosine.Medicine is placed (itp) respectively in lumbar injection (ip), intratumor injection (it) and tumor.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 10th day.
Table 3
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| ?1(6) | Contrast | ????78±12 | |
| ?2(6) | Vinorelbine (ip) | ????46±8.0 | ??＜0.05 |
| ?3(6) | Vinorelbine (it) | ????38±4.3 | ??＜0.01 |
| ?4(6) | Vinorelbine (itp) | ????26±2.4 | ??＜0.01 |
| ?5(6) | Vinmegallate (ip) | ????56±8.0 | ??＜0.01 |
| ?6(6) | Vinmegallate (it) | ????34±3.0 | ??＜0.01 |
| ?7(6) | Vinmegallate (itp) | ????18±2.0 | ??＜0.001 |
| ?8(6) | Vinleurosine (ip) | ????52±9.6 | ??＜0.001 |
| ?9(6) | Vinleurosine (it) | ????24±3.6 | ??＜0.001 |
| ?10(6) | Vinleurosine (itp) | ????12±3.6 | ??＜0.001 |
The result of embodiment 10 to 12 shows that used various plant alkaloid kind anti-cancer drugs all have the obvious suppression effect to growth of tumour cell when this concentration, but comparatively obvious with local application's effect, wherein locally places that to be that tumor is implanted into the most effective.Local placement not only can suppress tumor growth effectively, and can significantly reduce the general toxic reaction of medicine, and selected plant alkaloid kind anti-cancer drugs is of universal significance.
The result of embodiment 10 to 12 shows that tumor by local placement plant alkaloid kind anti-cancer drugs has obvious superiority, be further clear and definite slow release effect of the present invention, selected the copolymer (PLGA of polyglycolic acid and hydroxyacetic acid respectively for use, molecular weight is 10000), ethylene vinyl acetate copolymer (EVAc) and polifeprosan (to carboxy phenyl propane (p-CPP) and certain herbaceous plants with big flowers diacid (SA) copolymer) be that pharmaceutic adjuvant, gravimetry percentage ratio are the release conditions of 20% plant alkaloid kind anti-cancer drugs.The result shows that the drug release time of this anticancer pharmaceutical composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.Therefore the obvious tumor-inhibiting action that this anticancer pharmaceutical composition is described is mainly from its medicament slow release characteristic, and the latter is apparent at the superiority of keeping aspect the local drug concentration, and to selected plant alkaloid kind anti-cancer drugs tool universal meaning.Wherein PLGA is excellent than EVAc or polifeprosan.
As mentioned above, the preparation method of anticancer pharmaceutical composition of the present invention can be selected as the case may be.Anticancer pharmaceutical composition can be made various dosage forms with existing method, and therefore, above embodiment only is used for explanation, and is not limitation application of the present invention.Said composition except that independent application, also can with many treatment measure use in conjunction: as with use in conjunction such as radiotherapy, high thermal therapeutical, immunization therapy, phototherapy, electrotherapy.The local placement used said composition has uniqueness as synergist advantage and very high clinical value.When said composition and other treatment measure use in conjunction, said composition can be simultaneously or prior to other treatment measure.
Claims (10)
1. an anticancer pharmaceutical composition comprises anticancer effective component and pharmaceutic adjuvant, it is characterized in that anticancer effective component is the salt of plant alkaloid or plant alkaloid,
Described plant alkaloid is selected from leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, Podophyllinic Acid, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, Hainanensine, Hainanolide, vinpocetine, liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine, vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone, Mei Dengsu, rubescensine A, pretazettine, tazettine before the hydrochloric acid, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali;
The salt of described plant alkaloid is selected from sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, tartrate, succinate or maleate;
The salt of above plant alkaloid or plant alkaloid can singly select or multiselect.
2. according to the described anticancer pharmaceutical composition of claim 1, it is characterized in that the percentage by weight of salt in compositions of plant alkaloid or plant alkaloid is 0.01-99%.
3. the anticancer pharmaceutical composition according to claim 1 is characterized in that described plant alkaloid is:
(a) 1-50% leurosidine, Changchun indole, Changchun chlormethine, oxo bridge vinblastine, Podophyllinic Acid, tartaric acid F 81097, tartaric acid leurosine, leurosine, tartaric acid catharanthine, Hainanensine, Hainanolide or vinpocetine; Or
(b) 1-50% liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine; Or
(c) 1-50% vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine, aranotin, monocrotaline, maitansine, elliptinium acetate, total alkaloid of harmaline, heart chrysanthemum lactone or Mei Dengsu; Or
(d) tazettine, procarbazine, procarbazine hydrochloride, thalictrine, thalidasine, 2,3,5,6-tetramethoxyphenanthro[9,10:6',7', tylophorimidine or white cottonrose hibiscus alkali before 1-50% rubescensine A, pretazettine, the hydrochloric acid;
Below all be weight percentage.
4. the anticancer pharmaceutical composition according to claim 1 is characterized in that the described plant alkaloid 2-30% leurosidine that is weight percentage, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, Podophyllinic Acid, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, vinpocetine, liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, homoharringtonine or procarbazine.
5. the anticancer pharmaceutical composition according to claim 1 is characterized in that described plant alkaloid be weight percentage 1-20% vinorelbine and 1-20% leurosidine, the Changchun indole, the Changchun chlormethine, the oxo bridge vinblastine, Podophyllinic Acid, the tartaric acid F 81097, the tartaric acid leurosine, leurosine, the tartaric acid catharanthine, vinpocetine, liquor epinephrinae bitartratis ophthalmicus, vinorelbine, the two tartrates of vinorelbine, Vinorelbine tartrate, Vinmegallate, vinleurosine, vinleucinol, vinglycinate, Deacetylvincaleucoblastine 4-(N,N-dimethylglycinate) sesquisulfate, virosine, vinfosiltine, vinformide, vinflunine or vinepidine, vindesine, vinzolidine, vintriptol, vinrosidine, oxymatrine, cephalotaxin, 3(R)-Deoxyharringtonine, the combination of homoharringtonine or procarbazine.
6. the anticancer pharmaceutical composition according to claim 1 is characterized in that pharmaceutic adjuvant is selected from macromolecule polymer and composition thereof or copolymer.
7. the anticancer pharmaceutical composition according to claim 1, it is characterized in that pharmaceutic adjuvant be selected from the copolymer of polylactic acid, hydroxyacetic acid and glycolic, ethylene vinyl acetate copolymer, to carboxy phenyl propane/certain herbaceous plants with big flowers diacid copolymer and composition thereof or copolymer.
8. the anti-cancer composition according to claim 1 is characterized in that used pharmaceutic adjuvant is one of following:
A) molecular weight is the polylactic acid of 5000-15000,10000-20000,25000-35000 or 30000-50000;
B) molecular weight is the lactic acid of 5000-15000,10000-20000,25000-35000 or 30000-50000 and the copolymer of glycolic;
C) ethylene vinyl acetate copolymer;
D) 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid copolymer all is weight percentage;
E) xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or albumin.
9. the anticancer pharmaceutical composition according to claim 1 is characterized in that compositions is suspension, implant, slow releasing agent or implantation slow release agent.
10. the application of the described anticancer pharmaceutical composition of claim 1 is used to prepare the medicine that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410075842 CN1676165A (en) | 2004-12-29 | 2004-12-29 | In vivo slow-releasing anticancer medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410075842 CN1676165A (en) | 2004-12-29 | 2004-12-29 | In vivo slow-releasing anticancer medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1676165A true CN1676165A (en) | 2005-10-05 |
Family
ID=35049016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410075842 Pending CN1676165A (en) | 2004-12-29 | 2004-12-29 | In vivo slow-releasing anticancer medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1676165A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138612B (en) * | 2006-10-13 | 2011-12-07 | 桂林商源植物制品有限公司 | Antineoplastic preparations and method of preparing the same |
| CN103040823A (en) * | 2013-01-22 | 2013-04-17 | 杭州雷索药业有限公司 | Application of vinpocetine in preparation of anti-angiogenic medicament |
| KR101792031B1 (en) | 2012-01-13 | 2017-10-31 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
-
2004
- 2004-12-29 CN CN 200410075842 patent/CN1676165A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138612B (en) * | 2006-10-13 | 2011-12-07 | 桂林商源植物制品有限公司 | Antineoplastic preparations and method of preparing the same |
| KR101792031B1 (en) | 2012-01-13 | 2017-10-31 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
| CN103040823A (en) * | 2013-01-22 | 2013-04-17 | 杭州雷索药业有限公司 | Application of vinpocetine in preparation of anti-angiogenic medicament |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857221A (en) | Slow released anticancer medicien containing both platinum compound and its synergist | |
| CN1748671A (en) | Slow releasing injection containing anti-mitosis medicine | |
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN1676165A (en) | In vivo slow-releasing anticancer medicinal composition | |
| CN1634584A (en) | Anti-cancer medicine composition containing antimetabolite | |
| CN1304054C (en) | Combination of slow released anticancer medication | |
| CN1299774C (en) | Slow released anticancer combination of medication embedded the interior of the body | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN1824314A (en) | Slow release agent containing hormone kind anti cancer medicine | |
| CN1923281A (en) | Anti-cancer slow release injection comprising plant alkaloid | |
| CN1311818C (en) | Pharmaceutical composition for solid tumour | |
| CN100340296C (en) | Anticarcinogenic internal implant agent | |
| CN1857210A (en) | Slow released anticancer medicine with both antimetabolite and its synergist | |
| CN1686544A (en) | Anti entity tumour medicinal composition containing plant alkaloid | |
| CN101066454A (en) | Solid tumor treating medicine composition | |
| CN1311872C (en) | Anticancer combination of medication | |
| CN100350975C (en) | Anticarcinogen composition | |
| CN1299674C (en) | Slow released combination of anticancer drugs embedded in vivo | |
| CN1857215A (en) | Slow released injection containing antimetabolite | |
| CN1679951A (en) | Medicinal composition for tumor body | |
| CN1679936A (en) | Anticarcinogen composition | |
| CN101219104A (en) | Cladribine sustained-release implantation agent for treating solid tumors | |
| CN1923280A (en) | Anti-cancer slow release injection containing dichloroethylaminum | |
| CN1634583A (en) | Anti-cancer medicine composition containing antineoplastic antibiotics | |
| CN101229120A (en) | Sustained release implant for treating solid tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |